slick3333 Posted - 6 days ago

$MDXH still alone here but making small moves back up after hitting bottom few weeks ago

JonhanDAO Posted - 1 week ago

$MDXH Market Cap: 81045656 Forward P/E Ratio: -4.304348 Dividend Yield: N/A Earnings Per Share (EPS): -1.66 Price/Book Ratio: N/A Debt to Equity Ratio: N/A Get more info: https://www.openweb.com/share/2RAHIMDxYbCVOhuve5KHEj3SJst

Icarus81 Posted - 1 week ago

$MDXH Implemented $50M At-The-Market ("ATM") program to foster long-term shareholder development

DonCorleone77 Posted - 1 week ago

$MDXH MDxHealth announces debt refinancing with OrbiMed On May 1, 2024, mdxhealth closed a $100 million loan and security agreement with funds managed by OrbiMed Advisors. The Company drew down $55 million from this loan, replacing its existing $35 million debt funded by an affiliate of Innovatus Capital Partners, LLC. At the option of the Company, an additional $45 million can be drawn under the OrbiMed facility, consisting of a $25 million delayed draw term loan and a $20 million delayed draw term loan, in 2025 and 2026 respectively, subject to certain conditions. The loans are secured by substantially all assets of the Company, including intellectual property rights. Remaining proceeds of the loans will be used for working capital purposes and to fund general business requirements.

DonCorleone77 Posted - 1 week ago

$MDXH MDxHealth raises 2024 revenue view $83M-$85M from $79M-$81M Consensus $79.93M.

DonCorleone77 Posted - 1 week ago

$MDXH MDxHealth reports Q1 EPS (31c), consensus (30c) Reports Q1 revenue $19.8M, consensus $18.21M. Michael K. McGarrity, CEO of mdxhealth, commented: "We are pleased to report operating results that demonstrate successful execution of our growth strategy and support our outlook for delivering sustainable growth in revenues, a consistent reduction in cash burn, and adequate runway to achieve adjusted EBITDA profitability in the first half of 2025. Additionally, we have received the first clinical samples from current customers for hereditary germline testing and now expect germline testing to begin contributing to revenue in the second quarter. Based on this continued momentum in our execution and strong demand for our tests, we are increasing our 2024 revenue guidance to $83-85 million from the previous $79-81 million. "We are excited to partner with OrbiMed in a new debt facility, which provides significant growth capital and balance sheet flexibility, and allows the Company to further support growing demand for our precision diagnostic tests. This investment also reflects the continued progress we are making in attracting leading institutional investors who recognize our Company's unique positioning within our high growth, urology markets."

Stock_Titan Posted - 1 week ago

$MDXH MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed https://www.stocktitan.net/news/MDXH/m-dx-health-reports-q1-2024-results-and-announces-growth-capital-sm6bjpb8q0py.html

slick3333 Posted - 04/30/24

$MDXH another super super duper low volume day yay me!

slick3333 Posted - 04/26/24

$MDXH rough with no volume sucks but still hanging around

Rice1122 Posted - 04/18/24

$MDXH What is going on here? Any risk of dilution incoming?

Jodah Posted - 1 month ago

$MDXH guys ant target price or analysis you are kindly willing to share?

thingkfast Posted - 1 month ago

$MDXH any news for 15% move?

AmbushPredator Posted - 1 month ago

$MDXH interested in buying, but chances of an offering in the near future?

slick3333 Posted - 03/28/24

$MDXH back to the hole we came from….sighhh

thingkfast Posted - 03/28/24

$EXAS what’s the relationship here with $MDXH ?

TipRanks Posted - 03/28/24

These 2 ‘Strong Buy’ Penny Stocks Could Go Boom, Say Analysts https://www.tipranks.com/news/article/these-2-strong-buy-penny-stocks-could-go-boom-say-analysts-2 $LCTX $MDXH

slick3333 Posted - 03/20/24

$MDXH forgotten for sure….

HorsePicks Posted - 03/12/24

$MDXH Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering

Stock_Titan Posted - 03/12/24

$MDXH Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering https://www.stocktitan.net/news/MDXH/mdxhealth-adds-hereditary-prostate-cancer-genetic-test-to-prostate-uppuom7bkxbw.html

Jodah Posted - 2 months ago

$MDXH why the mega drop?

_www_larval_com_ Posted - 2 months ago

$MDXH just sunk -8% lower to -13% (~112Kv) in the last few minutes, follow for more volatility.

bealm Posted - 2 months ago

$MDXH below the radar. Clearly a BO opportunity and if not even better

3dancers Posted - 2 months ago

$MDXH oversold

tradethehalt Posted - 2 months ago

$MDXH trade halt (LUDP) was alerted to our Members at 10:41am EST. Halt price: $2.93 Vol: 118.68K.

Rollercoaster22 Posted - 2 months ago

$MDXH Yesterday DAWN, today MDXH. What's going on?

HaltTradeAlert Posted - 2 months ago

$MDXH Halt Time: 10:41:37 Issue Symbol: MDXH Reason Code: LUDP Stock Price: $2.9300 Market Cap: 88.593M Volume: 118,678 Relative Volume: 1.86 Shares Float: 16.72M Get this alert real time and sent to your phone just like a text by going to our website and joining our community for FREE! We just launched this service! Help us spread the word ! www.HaltTradeAlert.com

_www_larval_com_ Posted - 2 months ago

$MDXH just stumbled -18% lower to -21% (~100Kv) in the last few minutes, follow for more volatility.

Quantumup Posted - 2 months ago

BTIG⬆️ $MDXH $8 was $7/Buy~MdxHealth is an attractive small-cap growth/value stock, positioned as a one-stop-shop in prostate diagnostics testing, that executed nearly flawlessly operationally in '23/reported it's evaluating a # of growth opps in the form of new p'ships or possible M&A. $exas

DonCorleone77 Posted - 2 months ago

$MDXH MDxHealth sees 1H adjusted EBITDA profitability in 2025 The Company is maintaining its previously issued 2024 revenue guidance of $79-81M and confirms its view of expected adjusted EBITDA profitability in the first half of 2025.

DonCorleone77 Posted - 2 months ago

$MDXH MDxHealth reports Q4 EPS (39c) vs (76c) last year Reports Q4 revenue $19.4M, consensus $18.14M.Michael K. McGarrity, CEO of mdxhealth, commented: "Our fourth quarter and full year 2023 results reflect our continued commitment to commercial execution and operational discipline that has driven significant gross margin expansion across our business. With each passing quarter, we continue to build on our position as a leading precision diagnostics company rooted in our industry-leading technology, focus on the highest quality customer experience, and our unwavering commitment towards improving patient outcomes. We remain well positioned to build upon this success as we actively evaluate multiple, high-growth opportunities that could further strengthen and complement our existing menu. In 2024, we expect to deliver continued topline growth and operating execution that will lead to adjusted EBITDA profitability in the first half of 2025." Reports Q4revenue $19.4M, consensus $18.14M